

OLYMPIC MEDICAL CENTER
JANUARY 1, 2021 TO December 31, 2021 CUMULATIVE ANTIMICROBIAL % SUSCEPTIBLE REPORT

Gram Negative Organisms	Max # isolates Tested	Ampicillin	Ampicillin/Sulbactam	Cefazolin	Cefepime	Cefoxitin	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Imipenem ¹	Levofloxacin	Nitrofurantoin ²	Piperacillin/Tazobactam	Tobramycin	Trimethoprim/Sulfamethoxazole	% ESBL Negative		
<i>Escherichia coli</i>	1933	68	75	96	98	95		97	90	100	97	100	90	97	98		85	98		
<i>Citrobacter freundii</i> complex	58			0	98	0		88	98	100	95	100	98	92	88		90			
<i>Citrobacter koseri</i>	37			100	100	89		100	100	100	100	100	100	77	100		97			
<i>Klebsiella (Enterobacter) aerogenes</i>	42			0	99	0		90	100	100	100	100	100	9	90		100			
<i>Enterobacter cloacae</i> complex	77			0	99	0		88	99	100	97	100	99	26	89		96			
<i>Klebsiella pneumoniae</i>	284	0	89	96	97	96		97	96	100	96	100	96	26	99		92	97		
<i>Klebsiella oxytoca</i>	96	0	56	84	99	97		99	98	100	99	100	97	75	95		94	97		
<i>Morganella morganii</i>	34	0	12	0	100	47		100	76	100	100		82	0	100		94			
<i>Proteus mirabilis</i>	159	86	91	94	99	96		99	89	100	94		92	0	99		89			
<i>Serratia marcescens</i> ³	54			0	94	0		96	100	100	100		100	0			100			
<i>Acinetobacter Baumannii</i> ³	38		100				79		95		100	100	100		84	100	100			
<i>Pseudomonas aeruginosa</i>	194				96		95		89		95	95	84		100	100				
<i>Haemophilus influenzae</i> ³	18	94% Beta-lactamase negative																		

Denotes Drug of Choice

Numbers in **bold** represent % susceptible, blank cells represent drug not tested

¹ Meropenem susceptibilities can be inferred from imipenem results

² Tested only on urine isolates

³ Percent susceptible calculated on data from 1/1/20 through 12/31/21 in order to obtain the standard recommendation of 30 isolates (some we were unable to get the full 30 isolates)

OLYMPIC MEDICAL CENTER
JANUARY 1, 2021 TO December 31, 2021
CUMULATIVE ANTIMICROBIAL SUSCEPTIBILITY REPORT

Gram Positive Organisms	Max # Isolates Tested	Ampicillin	Cefotaxime	Ceftriaxone	Ciprofloxacin	Clindamycin ¹	Daptomycin	Doxycycline	Erythromycin	Gentamicin High Level ²	Levofloxacin	Linezolid	Nitrofurantoin ³	Oxacillin	Penicillin	Tetracycline	Trimethoprim/Sulfamethoxazole	Vancomycin
<i>Staphylococcus aureus</i> (MSSA)	427				81	84		99	72				100	100*			97	100
<i>Staphylococcus aureus</i> (MRSA) ⁴	252				19	66	100	97	12			100	100	0			80	100
<i>Coagulase Negative Staphylococcus</i>	126				73	53(17)		90	48				98	53			63	100
<i>Staphylococcus Lugdunensis</i>	39				100	77		100	85				100(16)	82			97	100
<i>Enterococcus faecalis</i>	294	100			88		100			84	88		99			24		100
<i>Enterococcus faecium</i> ^{5, 6}	22	59			41					86	41	100	9(11)			50		82
<i>Streptococcus pneumoniae</i> ^{5, 7}	38		100	100					64		100				95			100

Numbers in **bold** represent % susceptible. Blank cells represent drug not tested

Denotes Drug of Choice

*Not reported on urine isolates

¹ Inducible clindamycin resistance: MRSA 3%, MSSA 9%, *Coagulase Negative Staph* 6%, *S. lugdunensis* 3%

² Aminoglycosides are tested at high levels against *Enterococcus* species to indicate susceptibility to “synergy dosing” in endocarditis (low dose aminoglycoside plus cell wall active agent)

³ Antibiotic tested on urine isolates only

⁴ %MRSA/all *S. aureus* isolates = 37%

⁵ Percent susceptible calculated on data from 1/1/20 through 12/31/21 in order to obtain the standard recommendation of 30 isolates. These isolates were counted from Respiratory and Blood culture specimens.

⁶ 18% of *Enterococcus faecium* (and 0% of *Enterococcus faecalis*) were resistant to vancomycin (VRE)

⁷ *Streptococcus pneumoniae* isolates are screened for resistance to penicillin. Those isolates exhibiting resistance to penicillin and all isolates from blood and CSF are tested with additional antibiotics. Data listed are based on non-meningitis breakpoints.

*May infer sensitivity to: Cefazolin (other Drug of Choice in serious infection); Ampicillin-Sulbactam, Amoxicillin-Clavulanate, Cephalexin